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Abstract: The initial heart is composed of a myocardial tube lined by endocardial cells. The 
TGF superfamily is known to play an important role, as BMPs from the myocardium signal 
to the overlying endocardium to create an environment for EMT. Subsequently, BMP and 
TGF signaling pathways synergize to form primitive valves and regulate myocardial 
growth. In this study, we investigated the requirement of BMP activity by transgenic  
over-expression of extracellular BMP antagonist Noggin. Using Nfatc1Cre to drive  
lineage-restricted Noggin within the endocardium, we show that ectopic Noggin arrests cardiac 
development in E10.5-11 embryos, resulting in small hearts which beat poorly and die by 
E12.5. This is coupled with hypoplastic endocardial cushions, reduced trabeculation and fewer 
mature contractile fibrils in mutant hearts. Moreover, Nfatc1Cre-mediated diphtheria toxin 
fragment-A expression in the endocardium resulted in genetic ablation and a more severe 
phenotype with lethality at E11 and abnormal linear hearts. Molecular analysis demonstrated 
that endocardial Noggin resulted in a specific alteration of TGF/BMP-mediated signal 
transduction, in that, both Endoglin and ALK1 were downregulated in mutant endocardium. 
Combined, these results demonstrate the cell-autonomous requirement of the endocardial 
lineage and function of unaltered BMP levels in facilitating endothelium-cardiomyocyte 
cross-talk and promoting endocardial cushion formation. 
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1. Introduction 
Following differentiation from multipotent cardiac field progenitors, the endocardial cells give rise 
to an internal epithelial layer adjacent to the myocardium of the initially linear embryonic heart [1–3]. 
They form an endocardial tube by vasculogenesis and subsequently become the endocardium of the  
heart [4]. As development proceeds, endothelium-cardiomyocyte cross-talk helps to form specialized 
structures of the heart such as heart valves and myocardial trabeculae [5]. 
Concomitant with looping to enable formation of a four-chambered heart, trabeculation initiates and 
primitive cardiomyocytes form highly organized muscular ridges that are lined by layers of invaginated 
endocardial cells [6,7]. Several studies have established that the endocardial lineage plays an important 
role in spatial-temporal control of myocardial trabecular growth via endocardial Notch1-mediated 
Bmp10/Neuregulin-1/ErbB signaling in adjacent cardiomyocytes [8–11], and that endocardial Fkbp1a 
is required for modulation of Notch1 activity during ventricular wall formation [12]. Conversely, VEGF 
and Angiopoietin signal from the myocardium to the endocardium to regulate trabeculation [13,14]. In 
parallel, valve formation originates from a subpopulation of endocardial cells lining the myocardium 
that undergo endothelial-mesenchymal transition (EMT), proliferate and migrate into the extracellular 
matrix/cardiac jelly to form bilateral cardiac cushions in both the atrioventricular canal and the outflow 
tract [5,15,16]. Appropriate placement of the cushions is thought to be the development of the primary 
heart tube as a segmented organ, as well as the subsequent looping of the heart [17]. Significantly,  
Bmp2 [18,19], Bmp4/Bmp6 [20] and Msx1/Msx2 [21] all exhibit restricted expression within the AV 
canal and outflow tract myocardium and are thought to be inducers of endocardial cushion. Similarly, in 
addition to Notch [11] and its ligands Jag1 and Jag2 [22], Type I BMP receptors, ALK2 and ALK3 and 
TGF superfamily co-factor Smad4 [23] are present in the adjacent endocardium [19,24] and are thought 
to initiate EMT [25]. Subsequently, both BMP and TGF signaling synergize with Notch to promote the 
transition of endothelia to mesenchyme and the mesenchymal cell invasiveness [26,27]. 
BMPs have diverse roles in cardiomyocyte formation and maturation, valve development, 
trabeculation and embryonic cardiac morphogenesis. Moreover, numerous BMP ligands and receptors 
are expressed at high levels in the developing mouse heart and both systemic and conditional knockout 
mouse approaches have demonstrated that the majority of individual components play critical roles in 
early cardiac development [26]. However, the detailed molecular mechanisms regulated by BMP remain 
poorly understood due to the large number of family members with overlapping functions, parallel 
pathways, genetic redundancy and functional compensation. In order to begin to understand the role that 
blanket BMP signaling suppression may play in congenital heart defect pathogenesis and the 
spatiotemporal requirement of BMP function within the embryonic endocardium, we used the 
endocardially-restricted Nfatc1Cre knockin line to induce tissue specific expression of the BMP 
extracellular antagonist Noggin. Importantly, the endocardium comprises a unique endothelial cell 
population that expresses Nfatc1 during development, whereas vascular endothelial cells do not express 
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Nfatc1 [28–30]. Additionally, although endogenous Noggin is transiently expressed in the heart-forming 
region during gastrulation and is thought to act at the level of induction of mesendoderm to establish 
conditions conducive to cardiogenesis [31] and systemic loss of Noggin results in mutant mouse embryos 
with a thicker myocardium and larger endocardial cushions [32], endogenous Noggin is not present in 
either the E9.5 and older myocardium nor endocardium [19]. Indeed, exogenous Noggin blocks AVC 
explant EMT in culture [18]. Herein, we show that ectopic Noggin expression within the endocardium 
results in embryonic lethality, undersized bradycardic hearts with immature cardiomyocyte contractile 
apparatus, hypoplastic endocardial cushions and both BMP and TGF downstream effector altered 
expression profiles. Moreover, a similar phenotype but earlier time of lethality was observed when the 
endocardium was genetically ablated. Taken together, these results indicate that a distinct level of BMP 
activity is necessary for endocardial-cardiomyocyte cross-talk, and that suppression of BMP signaling 
results in both heart valve and myocardial trabeculae defects within the developing mouse heart. 
2. Materials and Methods 
Genetically modified mouse models: pMes-Noggin floxed conditional overexpression mouse  
model [33] was crossed with Nfatc1Cre knockin mice [3] to generate mutant embryos expressing  
Noggin within the endocardium and cushion mesenchyme derived from the endocardial lineage.  
pMes-Noggin/Nfatc1Cre mice (hereafter called NogEnd) were placed on ROSA26r (R26r) indicator 
background [34] for lineage mapping and to assess lineage-restricted Cre-mediated induction of Noggin 
expression. Yolk sac or tail tissue genomic DNA was genotyped, using two sets of primers: for Cre  
(5’-AATAAGCCTGCCGTGGTCACTGG; 3’-AACCCTGGACGCCTGGGACAC for detection of 
wildtype and 5’-GAAGCAACTCATCGATTGATTTACG; 3’-AACCCTGGACGCCTGGGACAC for 
detection of mutant) and Noggin (5’-CCCCCTGAACCTGAAACATA; 3’-GGCGGATGTGTA 
GATAGTGCT). Nfatc1Cre knockin mice were crossed to ROSA26eGFPDTA mice (R26rDTA; [35]) to 
genetically ablate the Nfatc1Cre lineage in utero and genotyped as previously described [36].  
Animal procedures and experimental conditions were refined to minimize harm to animals and 
performed with the approval of the Institutional Animal Care and Use Committee of Indiana University 
School of Medicine. 
Measuring heartbeat: Individual whole E11 embryos (with deciduae and embryonic blood vessels left 
attached) were dissected from the mother in 37 °C DMEM medium supplemented with 5% fetal calf 
serum (Gibco-BRL), placed in a closed 12 well culture tray and allowed to recover for 10 min in 
incubator (37 °C, 5% CO2), as previously described [37]. Each embryo was transilluminated and the 
heartbeat digitally recorded using an AxioCam MRc camera and dissecting scope (Zeiss) for 5 min and 
then PCR genotyped retrospectively. Heart rates were determined via calculating cardiac contractions/min 
in 7 control and 6 pMes-Noggin/Nfatc1Cre mutants (n = 4 litters). 
Immunohistochemistry, histology and X-Gal staining: Isolation of tissues, fixation, processing, and 
whole mount staining for -galactosidase and hematoxylin/eosin counterstaining was performed as 
described [36,38,39]. Subsequently, fixed embryos were sectioned at 6 m thickness. ABC kit 
(Vectorstain) with DAB and hydrogen peroxide as chromogens was used for signal detection as 
described [40]. The following primary antibodies were used: phospho-Smad1/5/8 (1:40,000, Cell 
Signaling), -Smooth muscle actin (1:5000, Sigma, St. Louis, MO, USA), PECAM-1 (1:200, BD 
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Biosciences Pharmingen, San Jose, CA, USA) and Periostin (1:10,000) as described [41]. For each assay, 
whole embryos and/or serial sections were examined for at least three individual embryos of each 
genotype at each stage of development. Collected from nine continuous sections of three individual 
samples of wildtype controls and mutants, respectively, data were subjected to Student’s t-test to 
determine the significance of differences. Wildtype littermates were always used as age-matched control 
samples (p values were assigned, with <0.05 being significant). 
Analysis of proliferation and apoptosis: Cell proliferation was examined via phospho-histone H3 
(1:500, Millipore) immunohistochemistry. Transverse serial sections of 6 μm paraffin-embedded 
embryos were stained with an antibody against pHH3 to identify mitotic cells and with hematoxylin to 
identify nuclei. DAB-positive cells were counted within both the atria and ventricles of 12 non-overlapping 
fields from at least 6 slides per embryo, and at least 3 embryos per genotype. The outcome of pHH3 
labeling was presented as percentage of labeled cells among total nuclei in the fixed hearts. Cell 
apoptosis was evaluated using TdT-FragEL™ DNA Fragmentation Kit (Calbiochem) following 
manufactures protocol. Apoptosis was determined via counting DAB-positive cells per 10,000 
ventricular cells counted from at least 6 slides per embryo, and at least 3 embryos per genotype. 
Confocal immunofluorescence: Embryos (n = 4 for each age group and genotype) were collected in ice 
cold PBS, fixed in 4% paraformaldehyde, and placed in sequentially higher sucrose solutions. Specimens 
were embedded in Tissue-Tek OCT, frozen at 80 °C and sectioned at 5 m. Immunostaining was 
performed using Vector Labs MOM fluorescent kit (FMK-2201) following the manufacturer’s protocol. 
Rhodamine phalloidin (1:100, Molecular Probes) and -Actinin (1:400, Sigma) were used. Stained 
sections were photographed using Zeiss Axioskop-2 plus microscope and AxioVision Rel.4.8 software. 
In situ hybridization and western blotting: Both radioactive and non-radioactive in situ hybridization 
analysis of Endoglin, Msx2 and Tgf1 expression were performed as described [42] using anti-sense  
S35-labeled and DIG-labeled (DIG RNA labeling mix, Roche) cRNA probes. Endoglin and Msx2 probes 
were provided by Helen Arthur [43] and Robert Maxson [21], and Tgf1 probe was described  
previously [44]. For all of these probes, serial sections were examined using at least three individual 
E10.5 embryos of each genotype. Western blotting was performed as described [45]. Proteins from E10.5 
isolated control and NogEnd hearts were probed with phospho-Smad1/5/8 (1:1,000, Cell Signaling), 
phospho-Smad3 (1:1,000, Epitomics), phospho-Smad2 (1:1,000, Cell Signaling), and loading control 
Tubulin (1:10,000, Sigma). Signal was detected via ECL-plus (Amersham) and densitometric 
quantification of Western data (n = 4 pooled hearts per genotype) was analyzed using the AlphaVIEW 
SA program. 
qPCR analysis: To verify Noggin induction in NogEnd mutants, we used qPCR on cDNA synthesized 
from pooled (n = 4 hearts of NogEnd and wildtype) E9.5 isolated hearts using a Superscript-II kit 
(Invitrogen). cDNA was amplified within the linear range using Noggin primers and normalized with 
GAPDH as described [40]. For expression profiling, mRNA from E10.5 isolated hearts (3 hearts per 
genotype) was isolated using RNAEasy (QIAGEN) kit and reverse transcribed using SuperScript II 
Reverse Transcriptase. Two samples/genotype were used in the Mouse TGF/Bmp Signaling Pathway 
RT2 Profiler PCR Array (Qiagen) and qPCR was done in technical triplicate for each sample. qPCR 
reaction was carried out using SyberGreenER (Invitrogen). All qPCR results are representative of three 
separate experiments (n = 3 plates/genotype) and Ct based fold-changes were calculated using 
GAPDH as a standard. 
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Statistical analysis: Statistical analysis was performed with Prism software (Graphpad Software, San 
Diego, CA, USA). Comparisons between experimental groups were made using unpaired student’s t test. 
A p-value < 0.05 was considered statistically significant. Densitometry analysis was examined for 
statistical significance using Student’s t-test. For statistical analysis of quantitative PCR data, pooled 
cDNA from wildtype and NogEnd hearts (n = 3 pooled E10.5 samples for each genotype) were analyzed 
in triplicate for each transcript. Error bars indicate standard error of the mean (SEM). 
3. Results 
3.1. Ectopic Noggin in the Nfatc1 Endocardial Lineage is Embryonic Lethal 
To assess the effects of BMP signaling suppression upon endocardial cell morphogenesis and 
function, we crossed Nfatc1Cre knockin mice [3] to pMes-Noggin transgenic mice [33] that have the 
mouse Noggin coding sequence cloned in front of the IRES-Egfp sequence under the control of the chick 
-actin promoter, with a floxed STOP cassette inserted between the -Actin promoter and the Noggin 
cDNA. As Noggin is a known secreted extracellular BMP antagonist [46,47] and Nfatc1Cre initiates  
Cre expression around E9 in the endocardium and is heart-restricted [3], thus over-expressing Noggin 
within the Nfatc1Cre lineage will suppress BMP signaling throughout early heart growth and endocardial 
development. These matings did not result in the birth of binary pMes-Noggin/Nfatc1Cre transgenic 
mutant mice (hereafter referred to as NogEnd mutants), although other genotypes were present at expected 
Mendelian ratios and were normal (n = 7 litters). Genotyping of embryos during gestation allowed 
recovery of mutant embryos at the expected ratios between E9 and 12.5; however, no viable NogEnd 
embryos were observed past E13 (n = 7 litters). At E9.5 and 10.5 NogEnd embryos were comparable in 
size and appearance as wildtype littermates (Figure 1A–D). However, by E11 NogEnd embryos appeared 
pale due to a decrease in circulating red blood cells within the mutant yolk sac, likely caused by a 
detectable decrease in heartbeat (n = 4 litters; controls= 273 ± 20 beats/min; NogEnd= 189 ± 34). 
Moreover, by E12 NogEnd mutants exhibit pooling of blood and undersized hearts when compared to 
wildtype littermates (Figure 1E,F). Additionally, the E12 mutant embryos were runted, the pharyngeal 
arches were hypoplastic and none survived until E13 (n = 7 litters). 
3.2. Molecular Characterization of Nog Phenotype 
As endogenous Noggin is not thought to be expressed in the E9.5 and older heart, and it is unclear 
whether the early embryonic endocardium expresses Noggin itself [19], we used non-radioactive in situ 
hybridization analysis to evaluate the spatiotemporal extent of endogenous and ectopic Noggin mRNA 
upregulation following loxP/Cre recombination in binary transgenic NogEnd mutants. As previously 
described [19], we confirmed that endogenous Noggin is expressed in the E8 control notochord and 
transiently within the E8.5 heart (not shown), but no endogenous Noggin is observed in control E10 
hearts (Figure 1G). In contrast, robust ectopic Noggin expression is present in the E10 NogEnd heart, 
specifically within the endocardium lining the atria and ventricles as well as the endocardially-derived 
cushion mesenchymal cells of the atrioventricular canal (Figure 1H,I) but is absent from the adjacent 
cardiomyocyte lineage and proepicardium/epicardium. To determine the level of transgenic Noggin 
induction, we used semi-quantitative RT-PCR measurement of pooled hearts (n = 4 hearts of NogEnd and 
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wildtype). Significantly, at both 30 and 34 cycles, Noggin was unregulated ×6.4 fold in isolated NogEnd 
mutant E9.5 hearts (Figure 1J). To define when and to what extent TGF superfamily signaling is 
suppressed via ectopic Noggin within the NogEnd endocardial lineage, we used Western blotting to 
determine resultant SMAD intracellular signal transducer expression levels (as there is no Noggin 
antibody). As TGF superfamily signaling from the cell membrane to the nucleus occurs via SMAD 
proteins [48], as expected, phospho-SMAD1/5/8 expression (a downstream effector of BMP ligand 
signaling) was suppressed ~65% in isolated E10.5 NogEnd hearts when compared to littermate controls 
(Figure 1K). Significantly, phospho-SMAD3 expression (a downstream effector of TGF ligand 
signaling) was also suppressed ~60% in isolated E10.5 NogEnd hearts, but phospho-SMAD2 expression 
(another downstream effector of TGF ligand signaling) remained unchanged (Figure 1K). 
Immunohistochemistry confirmed that phospho-SMAD1/5/8 expression was indeed suppressed in the 
NogEnd endocardial lineage and endocardially-derived cushions (Figure 1M,O), but not within the 
adjacent myocardium. pSMAD1/5/8 DAB-positive cells were counted within endocardium, trabeculated 
myocardium and AV/OT myocardium of three E10.5 control and mutant hearts. Significantly, per 
10,000 cells counted, NogEnd endocardium exhibited 42% less nuclear staining (2809 ± 14 stained mutant 
cells vs. 4895 ± 5 stained control cells; p  0.05). The E10.5 NogEnd trabeculated myocardium and 
AV/OT myocardium were largely unaffected (mutant trabeculated myocardium exhibited 4511 ± 29 
positive cells and the mutant AV/OT myocardium exhibited 5133 ± 22 positive cells per 10,000 total 
cells; whilst the control trabeculated myocardium exhibited 4604 ± 11 positive cells and the control 
mutant AV/OT myocardium exhibited 5002 ± 17 positive cells per 10,000 total cells; p  0.05). Jointly, 
these data show that Nfatc1Cre-mediated Noggin overexpression suppresses SMAD-dependent BMP and 
TGF signaling within only Cre-positive endocardium. 
3.3. R26r Reporter Analysis of Noggin Overexpressing Lineages 
As gross morphology established that overexpression of Noggin from E9 onwards within only the 
endocardium results in fully penetrant in utero lethality by E13; we placed pMes-Noggin/Nfatc1Cre mice 
onto the ROSA26r reporter background [34] to follow the fate of the Noggin overexpressing lineage and 
determine whether TGF superfamily suppression resulted in abnormalities in lineage specification as 
well as morphogenesis. Significantly, as expected, wholemount lacZ staining is heart-restricted and still 
present in E9.5 and E11 control and NogEnd mutant embryos (Figure 2A–D). Moreover, lacZ reporter is 
still present within E12 NogEnd hearts (Figure 2F) and persist until subsequent ~E13 embryo lethality, 
despite their dysmorphic appearance and reduced size, indicating that the endocardium survives ectopic 
Noggin induction. Consistent with the gross defects observed, histology confirmed that E10 and E10.5 
NogEnd endocadium is intact and continuously lines the trabeculae and interior of the heart (Figure 2G–O). 
Moreover, the E10 NogEnd heart structure and appearance is similar to control littermates, despite ectopic 
Noggin being present for at least ~6–12 h (Figure 2H). However, the E10.5 and E11 NogEnd 
atrioventricular and outflow tract cushions are reduced in cellularity and the endocardium is detached 
from the underlying mutant trabeculae (Figure 2J,L,O). Additionally, trabeculation of the E10.5 and 11 
NogEnd mutant heart ventricles is blunted, when compared to control littermates (Figure 2J,O). The 
trabeculation phase of cardiac development is initiated at the end of cardiac looping (E9.0 to E9.5 in 
mouse) and is defined as the growth of primitive cardiomyocytes to form the highly organized muscular 
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ridges that are lined by layers of invaginated endocardial cells [6,12]. Normally, newly formed 
trabeculae gradually contribute to the formation of the papillary muscles, the interventricular septum and 
compact at their base adjacent to the outer myocardium, adding substantially to ventricular wall 
thickness [7]. However, the NogEnd mutant trabeculae fail to continue their expansion and outgrowth, 
and the mutant endocardium is detached (Figure 2J,O). 
Figure 1. Ectopic Noggin in the Nfatc1 endocardial lineage is embryonic lethal.  
(A–F): Resultant phenotype of NogEnd mutant embryos (B,D,F) compared to wildtype 
littermate controls (A,C,E) at E9.5, 10.5 and 12. Wholemount right sided views show that 
E9.5 and 10.5 NogEnd embryos are grossly unaffected but that E12 NogEnd mutants are runted 
and exhibit pooling of blood in both blood vessels (indicated via arrow in F) and heart itself 
when compared to wildtype control littermates; (G–I): Non-radioactive in situ hybridization 
analysis using an anti-Noggin DIG-labelled probe confirms absent endogenous mRNA 
expression in control E10 heart (G) but robust endocardially-restricted transgenic Noggin 
(blue signal) in NogEnd mutant heart within cells lining the atria, atrioventricular cushions 
and ventricle. G’ and H’ inserts represent low power images of whole heart sections; (J): 
Semi-quantitative RT-PCR measurement of Noggin levels in control and mutant E9.5 pooled 
hearts (n = 4 of each genotype) confirmed elevated Noggin expression levels (×6.4) in the 
mutant hearts (data shown from 34 PCR cycles). Note, GAPDH loading control (upper panel J) 
is similar in both samples (data shown from 20 PCR cycles); (K): Western analysis of TGF 
superfamily downstream effector Smad signaling in pooled E10.5 hearts (n = 4 of each 
genotype) revealed NogEnd mutant isolated hearts exhibit reduced pSmad1/5/8 levels (only 
~35% of wildtype levels) when normalized to Tubulin levels, indicative of suppressed 
downstream BMP ligand signaling. Additionally, pSmad3 is similarly reduced in mutant 
hearts (only ~40% of wildtype levels), but pSmad2 levels remain unchanged. This suggests that 
downstream TGF ligand signaling is also partially suppressed; (L–O): Immunohistochemical 
analysis of pSmad1/5/8 in E10.5 control (L,N) and mutant (M,O) hearts demonstrates that 
expression is unaffected in cardiomyocytes but that pSmad1/5/8 expression (brown nuclear 
staining) is reduced in NogEnd mutant cushions compared to controls (* in (L)) and that 
pSmad1/5/8 expression is diminished within mutant endocardial cells (arrow in (O)) 
compared to wildtype controls (arrows in (N)). Scale bars: (G,H) = 20 μm; I = 50 μm. 
Abbreviations: lv, left ventricle; rv, right ventricle. 
 

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Figure 1. Cont. 
 
3.4. Immunohistochemical Analysis of NogEnd Mutant Growth and Development 
As NogEnd mutant hearts are smaller than control littermates, we sought to determine if the reduction 
in NogEnd heart size was a result of decreased proliferation, increased apoptosis, or both we used  
phospho-histone H3 (pHH3) immunostaining and TUNEL analysis (Figure 3). Significantly, 
proliferation within NogEnd mutant hearts was reduced ~30% (NogEnd 3005 ± 8 pHH3/9134 ± 17 total 
cells vs. control 4454 ± 13 pHH3/9473 ± 25 total cells; p  0.017) at E10.5 (Figure 3C,D), following 
counting of DAB-positive nuclear labelling compared to total nuclei counted from twelve sections of 
individual samples of wildtype controls and mutants (n = 3 for each genotype and 6 slides/embryo). 
Moreover, TUNEL analysis revealed that E10.5 mutant hearts exhibit apoptotic cells within the 
trabeculae adjacent to the overlying endocardium compared to zero apoptosis in control hearts (Figure 3D). 
Combined, the pHH3 and TUNEL data suggest that ectopic Noggin within the endocardium principally 
results in a smaller NogEnd heart size from E10.5 onwards due to a reduced cell proliferation rate, as well 
as subsequent programmed cell death in isolated NogEnd cardiomyocytes. As Nfatc1Cre (Figure 2) nor 
ectopic Noggin (Figure 1) are present within the cardiomyocyte lineage, this suggests that bystander or 
secondary signaling suppression from endocardium to adjacent cardiomyocytes is disturbed in  
NogEnd hearts.
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Figure 2. R26r reporter analysis of Noggin overexpressing lineages. (A–D): Left sided  
views of wholemount X-gal staining of control Nfatc1Cre/R26r (A,C) and mutant  
pMes-Noggin/Nfatc1Cre/R26r (B,D) embryos at E9.5 (A,B) and E11 (B,D) developmental 
stages, showing that Cre recombinase-mediated lacZ expression (blue) is restricted to the 
heart. Note lacZ staining reveals no obvious differences between control and NogEnd mutants 
hearts, although the E11 NogEnd mutant’s heart is smaller; (E,F): Isolated control and NogEnd 
E12 hearts viewed frontally, reveals that Nfatc1Cre/R26r–mediated lacZ reporter expression 
is still present in mutant heart (F) but that it is highly dysmorphic, misshapen and undersized; 
(G–O): Representative matched views of control E10 (G), E10.5 (I,K), E11 (M,N) and 
NogEnd mutant E10 (H), E10.5 (J,L), E11 (O) serial sections X-gal stained and 
counterstained with eosin. Transverse sections of E10 control (G) and NogEnd hearts (H) 
showed that lacZ expression was similarly localized in the endocardium and endocardial-derived 
cushion mesenchymal cells at the atrioventricular canals. E10.5 lacZ stained sagittal heart 
sections revealed that NogEnd mutant atrioventricular cushion is reduced in cellularity (arrow 
in (L)) when compared to control, littermate (K); Additionally, the NogEnd endocardium is 
detached from the underlying mutant trabeculae (J,L); Transverse sections of the X-gal stained 
E11 control (M,N) and mutant (O) hearts illustrates the hypoplastic endocardially-derived OFT 
(indicated via *) and atrioventricular cushions (arrow in (O)), the reduced trabeculae and 
detached endocardial lining; Note however, that NogEnd neural-crest-derived OFT cushions 
are grossly normal in cellularity (O); Scale bars: (A–F) = 100 μm; (G–L) = 20 μm;  
(M–O) = 100 μm. Abbreviations: la, left atria; lv, left ventricle; oft, outflow tract;  
rv, right ventricle. 
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Figure 3. Immunohistochemical analysis of NogEnd mutant growth and development.  
(A,B): Phospho-histone H3 examination of cell proliferation revealed that cell proliferation 
is slightly reduced ~30% within E10.5 mutant hearts, as illustrated via reduced DAB-positive 
(brown) nuclear staining in mutant (B) when compared to control littermate (A).  
Quantitative analysis indicates that the proliferation rate in mutant hearts is significantly 
reduced compared with the control sample. Data were averaged from 3 independent embryos 
with error bars indicating SD. * p < 0.05 (Student t test); (C,D): TUNEL analysis revealed 
that E10.5 mutant (D) hearts exhibit apoptotic cells (arrows in (D)) within the trabeculae 
adjacent to the overlying lacZ-postive endocardium compared to zero apoptosis in control 
hearts (C); Quantitative analysis indicates that apoptosis is only observed in the mutant 
ventricle. Data were averaged from 3 independent embryos with error bars indicating SD. * 
p < 0.05 (Student t test); (E,F): Expression of the endothelial cell adhesion and signaling 
receptor PECAM-1 confirms that the endocardium is still present and intact within NogEnd 
heart atria and ventricles, and that the mutant endocardial cells overlying the hypoplastic 
cushions (arrow in (F)) is unaffected. Note that the weaker PECAM-1 immunoreactivity in 
the control cushion is non-specific background staining, as endocardial cells undergoing 
EMT exhibit minimal to no pECAM-1 staining; (G,H): Reduced expression of the  
TGF-responsive endocardial cushion marker Periostin indicates that mutant endocardially-
derived cushions are anomalous (arrow in (H)) compared to control littermates (G); (I,J): 
Confocal immunofluorescent imaging of F-actin (red), Actinin (green) with DAPI nuclear 
staining (blue), reveals that while these cytoskeletal proteins are present within both control 
(I) and mutant (J) hearts, there are far fewer mature contractile fibrils within the E11 NogEnd 
mutant cardiomyocytes when compared to littermate controls. Moreover, the normal 
stratification of mature contractile apparatus within primarily the trabeculae rather than 
compact zone cardiomyocytes (indicated via red bar) observed in control heart (I) is not 
present in NogEnd mutant hearts (J); Scale bars: (A,B) = 50 μm; (C,D) = 10 μm; (E–H) = 20 μm. 
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In order to examine the integrity of the endocardium and to begin to assess the effects of ectopic 
Noggin upon endocardial gene expression and differentiation, we used immunohistochemistry to 
evaluate endothelial cell adhesion and signaling receptor PECAM-1 expression (also called CD31).  
As PECAM-1 is one of the earliest adhesion molecules whose expression is restricted to presumptive 
endothelial and endocardial cells [49], unaffected PECAM-1 staining confirms that the endocardium is 
still present and intact within NogEnd heart atria and ventricles, and that the mutant endocardial cells 
overlying the hypoplastic cushions is unaffected (Figure 3F). Confirming abnormal endocardial  
cushion morphogenesis and reduced phosphoSMAD3 suppression, NogEnd hearts exhibit reduced  
TGF-responsive endocardial cushion marker Periostin (Figure 3H). 
To understand the basis for the NogEnd bradycardia and cardiac failure leading to in utero lethality, 
we analyzed myofibril genes important for early cardiac contraction and generation of the heartbeat.  
As Smooth muscle actin is one of the first and transiently expressed microfilament proteins in the 
embryonic heart [50] we examined its expression first. Significantly, SMA was unaltered in NogEnd 
hearts and was not ectopically expressed (not shown). Subsequently, we used confocal analysis to 
examine F-actin (linear filament expression) and Actinin (localized to the Z-disk) expression within 
control and mutant cardiomyocyte contractile apparatus in detail. Although both these cytoskeletal 
proteins were present in E10 and E11 control and mutant cardiomyocytes, there are noticeably fewer 
mature contractile fibrils within the E11 NogEnd mutant cardiomyocytes when compared to littermate 
controls (Figure 3I,J). Moreover, the normal stratification of mature contractile apparatus within primarily 
the trabeculae rather than compact zone cardiomyocytes seen in control hearts, was not observed in NogEnd 
mutant hearts (Figure 3J). These data suggest that NogEnd myofibrillar maturation and expansion of the 
contractile apparatus may be compromised via ectopic Noggin expression in adjacent endocardium and 
suppression of TGF superfamily signaling resulting in contractile dysfunction. 
3.5. Nfatc1Cre Lineage is Required for Heart Development and in Utero Survival 
In order to determine the initial role of the endocardium within the whole embryo and specifically its 
functional requirement within the complex environment of the developing heart, we used genetic 
ablation via Cre/loxP and lineage-restricted induction of diphtheria toxin fragment-A expression. 
Nfatc1Cre knockin line was crossed with the R26rDTA knockin line [35], and the resultant embryos 
analyzed from E9 onwards (as Nfatc1Cre expression initiates E9 and DTA-mediated programmed cell 
death typically takes ~16–20 h for complete cell removal; [35]. Whole embryo analysis following
genetic cell ablation revealed that E9.5 Nfatc1Cre/DTA mutants are runted, have smaller hearts with an 
absence of a defined right ventricle when comparted to control littermates (Figure 4B) and appeared pale 
due to a decrease in circulating blood. Furthermore, E10.5 Nfatc1Cre/DTA mutants are severely growth 
retarded, exhibit widespread hemorrhaging and pooling of blood. Additionally, all the ablated mutants 
died between E10.5 and E11 with severe pericardial effusion, suggesting insufficient heart function 
(Figure 4D). The E10.5 Nfatc1Cre/DTA mutant hearts were hypoplastic and had failed to loop, resulting in 
dysmorphic linear hearts. Histology confirmed an absence of normal rightwards looping in ablated 
hearts, and also revealed that there is severe reduction of cardiomyocytes and almost a complete absence 
of trabeculae compared to control littermates (Figure 4H,J). As expected, there is significant apoptosis 
present in Nfatc1Cre/DTA hearts, particularly within the trabeculae forming region (Figure 4L). 
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Significantly, although lineage mapping at E11 in Nfatc1Cre;R26rDTA;R26r mutants confirms that the vast 
majority of the Nfatc1Cre marked endocardial lineage is absent, PECAM-1 staining confirms that there is still 
an endocardium present and mostly intact in E9.5 ablated mutant atria and ventricles (Figure 4N). Combined, 
these results substantiate that Nfatc1Cre lineage endocardial progenitors are essential for in utero survival and 
principally required during the trabeculation phase and endocardial cushion formation during cardiac 
development, likely through its functional regulation and support of adjacent cardiomyocytes. 
Figure 4. Nfatc1Cre lineage is required for heart development and in utero survival.  
(A–D): Whole embryo analysis following genetic cell ablation mediated via 
Nfatc1Cre;R26rDTA results in a smaller heart by E9.5 (B) and severe runting, pericardial 
effusion (indicated via arrow in D), widespread hemorrhaging and pooling of blood at E10.5 
(D,D’) when compared to control littermates. Growth retardation of the pharyngeal arches 
and heart is detectable by E9.5 and by E10.5 the ablation mutants are dying and have very 
small dysplastic linear hearts (D’) compared with controls (C); (E,F): Lineage mapping at 
E11 in control Nfatc1Cre;R26r and ablated Nfatc1Cre;R26rDTA;R26r mutants confirms that the 
vast majority of the Nfatc1Cre marked endocardial lineage is absent (no lacZ in heart, arrow 
in (F)) and that Cre expression is absent from the control yolk sac (E); (G–J): Histology 
reveals that ablated linear hearts (H,J) are smaller and abnormal and that there is severe 
reduction of cardiomyocytes and very little trabeculae compared to control littermates (G,I) 
in transverse H&E stained sections through the E9.5 outflow tract (G,H) and atrioventricular 
canal planes (I,J); (K,L): TUNEL analysis revealed that E9.5 mutant (L) hearts exhibit 
extensive apoptosis in both endocardial cells and cardiomyocytes (arrows in (L)) in ablated 
heart compared to no apoptosis in control (K); K’ and L’ inserts are low power views of the 
control (K’) and ablated mutant (L’) yolk sacs. Note there is no apoptosis within either yolk 
sac but that the ablated mutant yolk sac does not have mature vessels; (M,N): Expression of 
the endocardial marker PECAM-1 confirms that the endocardium is still present and intact 
in both E9.5 control (M) and ablated mutant (N) atria and ventricles. Scale bars: (G–J) = 20 μm; 
(K,L) = 10 μm. 
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3.6. qPCR mRNA Profiling and in Situ Verification of Expression Alterations 
To identify the endocardial targets that are altered via ectopic Noggin and the factors that may mediate 
endocardial-cardiomyocyte signaling during cardiac morphogenesis, we examined expression of TGF 
superfamily targets and genes known to be involved in BMP and TGF ligand downstream signaling by 
qPCR in isolated E10.5 hearts (n = 3 pooled isolated NogEnd and wildtype hearts, carried out in duplicate 
samples). The E10.5 stage was chosen as NogEnd mutants do not exhibit an overt phenotype at this age 
(Figure 1D), but do show pSMAD deviations (Figure 1K). Quantitative PCR using a custom array of 84 
genes related to TGF/BMP-mediated signal transduction, including SMAD, SMAD target genes, 
adhesion and extracellular molecules and transcription factors revealed significant changes in transcript 
levels of the 13 listed genes (Figure 5A). As proof of principle, it was significant that expression of 
Noggin was elevated almost×4 fold in NogEnd hearts. Meaningfully, neither Bmp2 nor Bmp4 were 
affected, and endocardially-restricted Tgf1, myocardial Tgf2 and Msx2 levels were unaltered. 
Similarly, Smad1-5 expression levels were normal. However, Tgf3 mRNA was downregulated ×1.9 
fold in NogEnd hearts (Figure 5A). 
This analysis further demonstrated that expression of Growth differentiation factor 2 (Gdf2), which 
is also known as embryonic liver-specific endothelial Bmp9, is upregulated ×1.7 fold in NogEnd hearts 
suggestive of misspecification. Collagen alpha-2(I) chain (Col1a2) expression is also upregulated ×1.5 
fold in Noggin overexpressing hearts, signifying excessive fibrillar collagen in NogEnd hearts.  
Most significant was the ×3.7 fold downregulation of endocardially-expressed Endoglin, a cell surface 
glycoprotein within the TGF receptor complex [51], within NogEnd hearts compared to control hearts 
(Figure 5A,C). The downregulation of Endoglin within the NogEnd endocardium was verified via in situ 
hybridization (Figure 5C). Correspondingly, Endoglin-null embryos with heart valve and septation 
defects do not progress beyond E10.5, fail to form mature blood vessels in the yolk sac, lack trabeculae 
and exhibit small hearts with an absence of a defined right ventricle and pericardial effusion [52].  
Thus, systemic loss of Endoglin in mice phenocopies the NogEnd and Nfatc1Cre; R26rDTA embryonic 
phenotypes and are similarly lethal prior to the fetal stage. Moreover, Activin receptor-like  
kinase-1/ALK1 (Acvrl1) is downregulated ×1.8 fold, and both Acvrl1 and Endoglin mutations are 
associated with Hereditary Haemorrhagic Telangiectasia diseases, characterized by bleeding from 
vascular malformations [52–54]. In contrast to Gdf2 upregulation, both widely expressed  
BMP-responsive Gdf3 and Gdf5 are downregulated. Similarly, BMP-responsive Sox4 and Dlx2 
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developmental process genes are downregulated in NogEnd hearts. Both TGF superfamily co-receptors 
Tdgf1 (also called Cripto-1) and TGF1-receptor Associate Protein-1 (Tgfrap1) are downregulated via 
ectopic Noggin expression within the mutant heart endocardium. Finally, the pan-TGF superfamily 
signaling negative regulator Smad7 [45,55] is also downregulated×1.85 fold in NogEnd hearts.  
Thus overall, expression profiling indicated that ectopic Noggin within the endocardium elicited a 
specific expression profile response in NogEnd hearts, rather than wholesale suppression of  
TGF/BMP-mediated signal transduction. Moreover, despite Noggin being known as principally a 
secreted extracellular BMP antagonist [46,47], both BMP and TGF downstream effectors were altered. 
Figure 5. qPCR mRNA profiling and in situ verification of expression alterations.  
(A): Quantitative PCR using a custom array of 84 genes responsive to TGFß superfamily 
signal transduction revealed statistically significant changes in transcript levels of the 13 
listed genes. Data are presented as a logarithmic plot of relative expression 
(mutant/wildtype), where a value of 1 indicates no difference between E10.5 NogEnd mutant 
and wildtype pooled hearts and values <1 indicate reduced expression. The biggest 
alterations were observed in Noggin levels, which were x4 fold elevated in mutant hearts; 
and Endoglin levels, which were×3.7 fold reduced in mutant hearts. Error bars represent 
SEM; (B,C): Reduced Endoglin expression levels were verified by radioactive in situ 
hybridization, as the E10.5 mutant heart (B) exhibits significantly less Endoglin mRNA 
throughout the endocardial lineage when compared to wildtype littermate (B); (D–G): As 
qPCR profiling did not reveal any alterations in either endocardially-restricted Tgf1 or 
myocardial Msx2 expression levels, we used in situ hybridization to examine whether spatial 
alterations were present in mutant hearts; Radioactive in situ hybridization revealed 
comparable Tgf1 mRNA expression in control (D) and mutants (E), and Msx2 was normally 
expressed within the controls (F) and NogEnd mutant (F) myocardium adjacent to the AV 
cushions. Abbreviations: avc, atrioventricular cushion; lv, left ventricle; rv, right ventricle. 
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4. Discussion 
The goal of this study was to determine the functional effects of loss of the endocardial lineage and 
ectopic Noggin-mediated suppression of BMP signaling during initial heart morphogenesis, 
trabeculation and endocardial cushion formation. Although endogenous Noggin is transiently expressed 
in the normal E8.75-9 mouse heart, and is thought to establish conditions conducive to cardiogenesis [19], 
the consequences of deregulated Noggin within the endocardial lineage are unclear. We utilized two 
complementary mouse model systems to demonstrate the cell-autonomous requirement of the 
endocardial lineage and function of unaltered BMP levels in facilitating endothelium-cardiomyocyte 
cross-talk and promoting mesenchyme formation in endocardial cushions of mouse embryos. 
Binary pMes-Noggin/Nfatc1Cre transgenic mutants exhibit smaller hearts that are bradycardic and all 
die mid-gestation. NogEnd lethality and slow heartbeat are most likely due to fewer contractile elements, 
a lack of maturation of the actin-myosin microfilaments and reduced proliferation, resulting in 
insufficient cardiac output to drive bloodflow throughout the embryo. Although the endocardium has 
recently been shown to serve as a de novo source for transient definitive haematopoietic progenitors [56], the 
pale appearance of the NogEnd E10.5 mutants is more likely due to a decrease in circulating blood rather 
than defects in yolk sac vasculogenesis and/or primitive hematopoiesis, especially as Nfatc1Cre-mediated 
Cre expression is restricted to the heart [3]. Notably, the Noggin-mediated alteration of contractile 
apparatus morphogenesis is consistent with in vitro studies using cultured chick precardiac 
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mesoendoderm and exogenous Noggin [57], in which SMA expression was unaltered but sarcomeric 
actinin, titin, sarcomeric myosin were all misexpressed. The hypoplastic NogEnd outflow tract and AVC 
endocardial cushion phenotype is consistent with in vitro data showing that Noggin blocks EMT [18]. 
Although Bmp4 null hearts exhibit similar proliferation and growth abnormalities and dysmorphic  
hearts [58], cTnT-Cre-mediated conditional deletion of Bmp4 does not affect heart size until fetal stages [59]. 
Similarly, Nkx2.5Cre conditional deletion demonstrated Bmp2 is required for formation of cardiac jelly 
and formation of the cardiac cushions [60]. Moreover, Flk1-Cre mediated loss of Alk3 (Bmpr1a) resulted 
in embryonic lethality by E11.5, severe abdominal hemorrhaging and endocardial cushion defects [61]. 
To complement the Noggin transgenic analysis, we further examined the functional requirement of the 
E9-10 endocardium using Cre/loxP-mediated genetic cell ablation via diphtheria toxin-A. Significantly, 
E9.5 Nfatc1Cre/DTA mutants are severely runted, exhibit dysplastic linear hearts that hardly beat, pooling 
of blood and 100% die by E11. While we cannot exclude the possibility that poor function may play a 
potential role within the looping abnormality, our previous data in which the sodium-calcium exchanger 
Ncx1 is deleted and results in an absent heartbeat and lethality at E10, the Ncx1 null hearts still undergo 
looping despite lack of any cardiac function [37]. Combined, these results demonstrate Noggin-mediated 
suppression of BMP signaling within the endocardium, as well as endocardially-restricted diphtheria 
toxin-A genetic ablation, both have profound affects upon the adjacent myocardium. 
As Noggin is usually known as a secreted extracellular BMP antagonist [46,47], it was somewhat 
surprising that the adjacent trabeculated myocardium and atrioventricular/outflow myocardium was 
unaffected (Figure 1). This result may be due, in part, to the observation that Noggin is directly expressed 
within the mutant endocardium and that it becomes detached from the underlying mutant trabeculae 
(Figure 2) resulting in a reduced ability to secondarily suppress myocardial phosphoSMAD levels, or that 
the levels of secreted Noggin are too low to suppress the robust phosphoSMAD signaling routinely 
observed in embryonic cardiomyocytes. In fact Noggin has been shown to exhibit concentration-dependent 
effects, including inducing downstream targets at low concentrations and repressing those same targets 
at high concentrations [62,63]. Thus, it is unlikely that the NogEnd myocardial phenotype is just a 
consequence of excess secreted Noggin secondarily affecting the adjacent myocardium. Rather, our data 
supports the hypothesis that endocardial-myocardial cross talk may regulate myofibril assembly. 
Precisely how this achieved and what role BMP signaling plays is presently unclear, but it has been 
demonstrated the endocardium can act as an active transendothelial physicochemical gradient for various 
ions [64] and that contractility of isolated cardiac muscle can be profoundly altered via the presence of 
intact endocardium [65]. Within the embryonic heart there is a close relationship between newly 
assembling myofibrils and the sarcolemma, and that interactions between the membrane and the 
myofibril promote the early steps of striated myofibril assembly in both heart and skeletal muscle [66,67]. 
Perhaps secreted Noggin or reduced endocardial BMP signaling (and consequent Endoglin/ALK1 
suppression) may aberrantly affected adjacent myocardial sarcolemma, resulting in lack of maturation 
of the contractile apparatus. This in vivo Noggin-mediated alteration of contractile apparatus 
morphogenesis is consistent with in vitro [57], in which SMA expression was unaltered via exogenous 
Noggin but sarcomeric actinin, titin, and sarcomeric myosin expression was affected. 
Perhaps one of the most interesting observations in this study is that ectopic endocardial Noggin 
results in suppression of both phosphoSMAD1/5/8 and phosphoSMAD3. As expected, Noggin 
overexpression resulted in reduced phosphoSMAD1/5/8 levels, confirming suppression of BMP 
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signaling. However, phosphoSMAD3 levels were also suppressed in NogEnd hearts (but not 
phosphoSMAD2), suggesting parallel suppression of TGF signaling. Although we do not yet know 
whether loss of BMP signaling results in a secondary loss of TGF signaling or whether Noggin can directly 
affect TGF signaling within the endocardium and/or adjacent cardiomyocytes, these data clearly 
demonstrate that phosphoSMAD2 and phosphoSMAD3 can be differentially regulated and phosphoSMAD3 
may have a more important developmental role than phosphoSMAD2 in TGF superfamily-mediated 
endothelium-cardiomyocyte cross-talk morphogenesis. These data may also indicate that blocking BMP 
signaling can disrupt other signaling pathways, thus normal endocardial-cardiomyocyte cross-talk 
development requires a balance of BMP-TGF signaling for normal cardiac morphogenesis. Although 
Noggin is usually known as a secreted extracellular BMP antagonist [46,47], there are reports that TGF 
inducing the phosphorylation of SMAD1 [68,69], which may reflect redundancy or cooperativity in 
signaling. Moreover, functional redundancies among endocardially expressed type-I BMP receptors 
have been suggested by the studies in which ALK2 or ALK3 were conditionally deleted [60,61,70,71], 
as ALK2 can bind TGF and Activin ligands in addition to BMPs. Similarly, Tgf2 has been shown to 
be an endocardial activation marker [72], Tgf2 is downregulated in Bmp2/Nkx2.5Cre conditional 
knockout hearts [60] and BMP2 can induce Tgf2 expression within mouse AVC explant assays [18]. 
Although BMP signaling in the myocardium can also regulate myocardial Tgf2 expression as evident 
in the Alk3 conditional knockout [73], it is clear that endothelium-cardiomyocyte cross-talk regulation 
involves the TGF superfamily as a whole. Indeed, Tgf2 knock-out mice, but not Tgf1 or Tgf3 knock-out 
mice, feature deficient EMT in the cardiac cushions initially [74] but subsequently exhibit enlarged 
hyperplastic cushions/valves. Significantly, Tie1-Cre endocardial-restricted loss of Smad4 results in an 
absence of EMT, acellular cushions, and reduced endocardial proliferation [23]; as well as severe 
runting, blood pooling in E11.5 mutants and 100% lethality by E12.5. Given that SMAD4 is common 
to both TGF and BMP signaling, this further supports the data that both TGF and BMP signaling play 
a role within the endocardium during early heart formation and unperturbed cross-talk is required for in 
utero survival. 
To extend the in vivo genetic analysis and phenotyping of mutant hearts, we examined the resultant 
TGF-BMP-mediated signal transduction expression profiles elicited via ectopic Noggin expression 
within the endocardial lineage. In addition to Noggin upregulation and mis-expression of eleven other 
effects (Figure 5), this work clearly shows that expression of Endoglin is robustly repressed within the 
endocardium. As systemic Endoglin null embryos phenocopy the NogEnd mutants and die at E11 with 
enlarged thin-walled ventricles, dilated OFT, cardiac cushions that lack mesenchyme cells, and 
angiogenic defects in yolk sac [52], Endoglin is a potential, if not likely, candidate for mediating the 
endocardial-cardiomyocyte cross-talk defects observed. The non-signaling receptor Endoglin is thought 
to function as a regulator of the cell-extracellular microenvironment, specifically within the process of 
EMT and TGF superfamily regulated activation and invasion pathways during cardiac development [75]. 
Indeed, co-expression of Endoglin is thought to influence which TGF isoforms are bound and which 
signaling responses are made [76], and in addition to TGFs, Endoglin can also interact with Activin-A, 
BMP7 and BMP2 ligands. Moreover, our expression profiling also revealed that Acvrl1 (ALK1) type I 
TGF receptor, which appears to signal through SMAD1 [77], is similarly downregulated. Interestingly, 
both ALK1 and Endoglin exhibit similar endothelial expression patterns and both act within the same 
signaling pathway resulting in hereditary hemorrhagic telangiectasia disease [78,79] and arteriovenous 
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malformations [80]. While we do not know how endocardial BMP suppression directly regulates 
expression of Endoglin in the NogEnd endocardium or whether this is a primary consequence of reduced 
phosphoSMAD levels, these studies indicate that both BMP and TGF downstream effectors were 
altered. Similarly, how endocardial BMP-TGF superfamily-mediated Endoglin suppression alters 
adjacent myocardial expression profiles still needs to be investigated. 
5. Conclusions 
Together with previous studies [23,24,74], our study suggests reciprocal BMP-TGF signaling 
between the endocardium and myocardium during early heart morphogenesis is critical for cardiac 
development, specifically seeding of the endocardial cushions, trabeculation and maturation of the 
contractile apparatus to enable maintenance of cardiac output and in utero survival. Expression profiling 
of these ectopic Noggin expressing NogEnd mutant hearts reveals that this endocardial-myocardial 
signaling involves coordinated BMP-TGF superfamily-mediated maintenance of Endoglin/ALK1 
endocardial expression and consequent regulation of myocardial growth and promotion of endocardial 
EMT to enable population of the cardiac cushions.  Combined, these results demonstrate that fine-tuning 
of TGF superfamily signaling within the endocardium is required for essential cellular and paracrine 
contributions to the growth of the embryonic myocardium and the development of the cardiac valves. 
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